MBX Biosciences
PublicMBX Biosciences is now publicly traded
The data on this page reflects MBX Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 16, 2024
Last Round
Follow-on Offering
Feb 4, 2026
Est. Valuation at Exit
$1.72B
Total Funding Raised
$690.3M
Company Overview
MBX Biosciences is a clinical-stage biopharmaceutical company that discovers and develops precision peptide therapies for the treatment of endocrine and metabolic disorders.
Sector
Healthcare
AI Layer
Non-AI
Keywords
MBX Biosciences Comparables
Compare MBX Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AstraZeneca | 84% | |
| Metsera | 67% | |
| Roche Holding | 66% |
For institutional investors. Book with your work email.
MBX Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Feb 4, 2026 | ||||
| Follow-on Offering | Sep 24, 2025 | ||||
| IPO | Sep 16, 2024 | ||||
| Series C | Aug 5, 2024 | ||||
| Series B | Nov 14, 2022 | ||||
Series A | Jul 27, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MBX Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | Follow-on Offering, IPO |
| RA Capital Management | Series C, Series B |
| Frazier Healthcare Partners | Series A |
| Guggenheim Securities | Follow-on Offering, IPO |
| New Enterprise Associates | Series C, Series A, Series B |
| BioCrossroads | Seed, Series A |
| Deep Track Capital | Series C |
For institutional investors. Book with your work email.
MBX Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.